



COPY OF PAPERS  
ORIGINALLY FILED

1646 #109  
PATENT  
18810-81401

Dmt.  
6-21-02

May 30, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Prezant et al.  
Serial No.: 09/854,326  
Filed: May 11, 2001  
For: METHOD OF REGULATING BIOLOGICAL ACTIVITY OF  
PITUITARY TUMOR TRANSFORMING GENE (PTTG)1  
USING PTTG2

Examiner: Unknown

Unit: 1646


Confirmation No.: 7808

RECEIVED  
JUN 14 2002  
TECH CENTER 1600/2900

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS	
WASHINGTON, D. C. 20231, ON	May 30, 2002 DATE
BY 	JAN WEISS
	May 30, 2002 (DATE OF SIGNATURE)

Applicant's attorney submits herewith Form PTO-1449,  
"Information Disclosure Statement" by Applicant referencing patents and/or  
other literature of which he is aware, that he believes may be material to the  
examination of this application and in respect of which there may be a duty to  
disclose in accordance with 37 C.F.R. § 1.56.

A copy of each of the disclosed patent documents and other  
references listed as other documents Nos. 78-79 are not being submitted  
herewith, because under Rule 37 C.F.R. § 1.98(d) this art was previously cited  
by the Examiner and/or the Applicant in connection with related applications  
U.S. Serial No. 09/569,956, filed May 12, 2000, and U.S. Serial No. 09/777,422,  
filed February 5, 2001. This previously filed Application was cited by applicant  
in this present Application per 35 U.S.C. § 120.

The filing of this Supplemental Information Disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists (37 C.F.R. 1.97(h)). Further the filing of this Supplemental Information Disclosure statement shall not be construed as an admission against interest in any manner.

It is believed that this Supplemental Information Disclosure statement is being filed before the mailing of a first office action on the merits. However, the Commissioner is hereby authorized to credit overpayments or charge any fees required under 37 C.F.R. 1.16 or C.F.R. 1.17 to Deposit Account No. 50-1597.

Respectfully submitted,

By: 

Nisan A. Steinberg, Ph.D.  
Registration No. 40,345

SIDLEY AUSTIN BROWN & WOOD LLP  
555 West Fifth Street  
Los Angeles, California 90013-1010  
Ofc: 213/ 896-6665  
Fax: 213/896-6600